Dexcom

DXCM · Nasdaq · Health Care

☆ Follow

Shareholder advocacy aimed at Dexcom

Nothing recorded yet. That means no campaign in our database names this company, not that none exists.

What shareholders voted on

From Dexcom’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.

2026

Item	Kind	Support	Outcome
Approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in the proxy statement for the Annual Meeting (which disclosure includes the Compensation Discussion and Analysis, the compensation tables and the narrative disclosures that accompany the compensation tables in such proxy statement), as follows	Say on pay	88.3%	Passed
Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows	Auditor	99.9%	Passed
Election of Rimma Driscoll	Director	99.8%	Passed
Election of Kyle Malady	Director	99.7%	Passed
Election of Renée Galá	Director	99.6%	Passed
Election of Rick Osterloh	Director	99.6%	Passed
Election of Jacob Leach	Director	99.3%	Passed
Election of Dr. Euan Ashley	Director	98.5%	Passed
Election of Mark Foletta	Director	98.2%	Passed
Election of Kevin Sayer	Director	97.8%	Passed
Election of Richard Collins	Director	96%	Passed
Election of Steven Altman	Director	95.1%	Passed
Election of Bridgette Heller	Director	94.5%	Passed
Election of Nicholas Augustinos	Director	84.7%	Passed

2025

Item	Kind	Support	Outcome
Approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in the proxy statement for the Annual Meeting (which disclosure includes the Compensation Discussion and Analysis, the compensation tables and the narrative disclosures that accompany the compensation tables in such proxy statement), as follows	Say on pay	89.6%	Passed
Dexcom stockholders approved the A&R 2015 ESPP, as follows	Company proposal	99.7%	Passed
Dexcom stockholders approved the A&R 2015 EIP, as follows	Company proposal	95.2%	Passed
Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom’s independent registered public accounting firm for the fiscal year ending December 31, 2025, as follows	Auditor	94.6%	Passed
Election of Renée Galá	Director	99.8%	Passed
Election of Rimma Driscoll	Director	99.7%	Passed
Election of Kyle Malady	Director	98.3%	Passed
Election of Richard A. Collins	Director	98.3%	Passed
Election of Mark G. Foletta	Director	97.8%	Passed
Election of Steven R. Altman	Director	97%	Passed
Election of Bridgette P. Heller	Director	95.1%	Passed
Election of Kevin R. Sayer	Director	94.9%	Passed
Election of Nicholas Augustinos	Director	88.3%	Passed

2024

Item	Kind	Support	Outcome
Dexcom stockholders approved, on a non-binding advisory basis, a stockholder proposal regarding transparency in lobbying, as follows	Shareholder proposal	51.9%	Passed
Dexcom stockholders did not approve, on a non-binding advisory basis, a stockholder proposal regarding pay equity disclosure, as follows	Shareholder proposal	35.9%	Failed
Approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in the proxy statement for the Annual Meeting (which disclosure includes the Compensation Discussion and Analysis, the compensation tables and the narrative disclosures that accompany the compensation tables in such proxy statement), as follows	Say on pay	90.2%	Passed
Eric J. Topol, M.D	Company proposal	97.8%	Passed
Dexcom stockholders ratified the selection by the audit committee of the board of directors of Ernst & Young LLP as Dexcom’s independent registered public accounting firm for the fiscal year ending December 31, 2024, as follows	Auditor	93.4%	Passed
Election of Rimma Driscoll	Director	99.9%	Passed
Election of Karen Dahut	Director	99%	Passed
Election of Kyle Malady	Director	98.5%	Passed
Election of Richard A. Collins	Director	98.5%	Passed
Election of Steven R. Altman	Director	97.3%	Passed
Election of Bridgette P. Heller	Director	97%	Passed
Election of Mark G. Foletta	Director	97%	Passed
Election of Kevin R. Sayer	Director	94.2%	Passed
Election of Nicholas Augustinos	Director	93.1%	Passed

2023

Item	Kind	Support	Outcome
Eric J. Topol, M.D	Company proposal	99.1%	Passed
Election of Karen Dahut	Director	99%	Passed
Election of Kyle Malady	Director	97.8%	Passed
Election of Richard A. Collins	Director	97.6%	Passed
Election of Mark G. Foletta	Director	97.5%	Passed
Election of Steven R. Altman	Director	96.8%	Passed
Election of Barbara E. Kahn	Director	96.3%	Passed

2022

Item	Kind	Support	Outcome
Election of Kyle Malady	Director	97.4%	Passed
Election of Steven R. Altman	Director	96.2%	Passed
Election of Barbara E. Kahn	Director	95.4%	Passed
Election of Jay S. Skyler	Director	85.7%	Passed

2021

Item	Kind	Support	Outcome
Election of Bridgette P. Heller	Director	99%	Passed
Election of Kevin R. Sayer	Director	96.3%	Passed
Election of Nicholas Augustinos	Director	83.9%	Passed

2020

Item	Kind	Support	Outcome
Eric J. Topol, M.D	Company proposal	97%	Passed
Election of Richard A. Collins	Director	99.5%	Passed
Election of Mark G. Foletta	Director	97.6%	Passed

2019

Item	Kind	Support	Outcome
Election of Barbara E. Kahn	Director	99.7%	Passed
Election of Steven R. Altman	Director	91.5%	Passed
Election of Jay S. Skyler	Director	87.6%	Passed

2018

Item	Kind	Support	Outcome
Election of Kevin Sayer	Director	99.7%	Passed
Election of Nicholas Augustinos	Director	98.3%	Passed
Election of Terrance H. Gregg	Director	98.2%	Passed

Proxy statements and vote results

Straight from Dexcom’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.

Year	Filing	Filed
2026	Vote results	2026-05-28
2026	Proxy statement	2026-04-15
2025	Vote results	2025-05-09
2025	Proxy statement	2025-03-27
2024	Vote results	2024-05-24
2024	Proxy statement	2024-04-22
2023	Vote results	2023-05-19
2023	Proxy statement	2023-04-06
2022	Vote results	2022-05-20
2022	Proxy statement	2022-04-08
2021	Vote results	2021-05-21
2021	Proxy statement	2021-04-09
2020	Vote results	2020-05-22
2020	Proxy statement	2020-04-10
2019	Vote results	2019-06-04
2019	Proxy statement	2019-04-19
2018	Vote results	2018-06-04
2018	Proxy statement	2018-04-20

Do you represent Dexcom? Claim this profile to respond to the campaigns listed here.

← All companies